Table 3.
Univariate Regression Analysis of Variables Associated with Oxygen Desaturation During the 6-Min Walk Test in Patients with Chronic Obstructive Pulmonary Disease
| Subjects | Univariate | ||
|---|---|---|---|
| OR | 95% CI | P value | |
| Sex (male vs female) | 0.90 | 0.70–1.16 | 0.4318 |
| Age (years) | 1.02 | 1.01–1.03 | 0.0002 |
| BMI | 0.96 | 0.94–0.98 | 0.0002 |
| FEV1% predicted | 0.96 | 0.96–0.97 | <0.0001 |
| Hypertension | 1.50 | 1.16–1.93 | 0.0021 |
| Diabetes | 1.19 | 0.84–1.70 | 0.3350 |
| Angina pectoris | 0.84 | 0.52–1.36 | 0.4782 |
| Myocardial infarction | 0.57 | 0.22–1.47 | 0.2437 |
| Ischemic heart disease | 1.33 | 0.81–2.17 | 0.2565 |
| Atrial fibrillation | 1.99 | 1.11–3.56 | 0.0204 |
| Heart failure | 2.41 | 1.43–4.07 | 0.0010 |
| Stroke | 1.48 | 0.69–3.15 | 0.3119 |
| Peripheral arterial disease | 4.50 | 0.53–38.62 | 0.1699 |
| SABA (total) | 2.64 | 1.85–3.75 | <0.0001 |
| SABA (oral) | 1.97 | 1.17–3.29 | 0.0102 |
| SABA (inhaled) | 2.56 | 1.78–3.67 | <0.0001 |
| SAMA | 2.54 | 1.70–3.79 | <0.0001 |
| SABA+SAMA | 2.52 | 1.55–4.10 | 0.0002 |
| Ultra-LABA | 1.06 | 0.73–1.53 | 0.7610 |
| LAMA | 1.84 | 1.44–2.36 | <0.0001 |
| LABA+LAMA | 0.87 | 0.55–1.36 | 0.5415 |
| ICS+LABA | 1.73 | 1.36–2.22 | <0.0001 |
| Xanthine | 1.45 | 1.09–1.92 | 0.0111 |
| Oral steroid | 1.80 | 1.33–2.43 | 0.0001 |
| β-blocker | 1.15 | 0.75–1.76 | 0.5160 |
| β1-selectivity | 1.22 | 0.75–1.98 | 0.4353 |
| Non-β1-selectivity | 1.05 | 0.48–2.28 | 0.9075 |
| CCB | 0.99 | 0.73–1.35 | 0.9613 |
| DHP | 0.92 | 0.65–1.28 | 0.6032 |
| Non-DHP | 1.47 | 0.78–2.76 | 0.2300 |
Note: Data are presented as N, N (%), or mean±SD.
Abbreviations: CCB, calcium channel blockers; DHP, dihydropyridine; SABA, short-acting β-agonists; SAMA, short-acting muscarinic antagonists; LABA, long-acting β-agonists; LAMA, long-acting muscarinic antagonists; ICS, inhaled corticosteroids.